RaySearch Laboratories (Q4 Review): A beaming end it was - Redeye
Q4 beat our sales estimates and came in line with our EBIT forecast. The recent share price collapse makes stock repurchases a very attractive option relative to the proposed dividend payout.
ANNONS
Q4 beat our sales estimates and came in line with our EBIT forecast. The recent share price collapse makes stock repurchases a very attractive option relative to the proposed dividend payout.
